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Abstract
Background: Breast cancers are more frequently diagnosed at an early stage and currently have improved long
term outcomes. Late normal tissue complications induced by adjuvant radiotherapy like secondary cancers or
cardiomyopathy must now be avoided at all cost. Several new breast radiotherapy techniques have been
developed and this work aims at comparing the scatter doses of internal organs for those techniques.
Methods: A CT-scan of a typical early stage left breast cancer patient was used to describe a realistic
anthropomorphic phantom in the MCNP Monte Carlo code. Dose tally detectors were placed in breasts, the heart,
the ipsilateral lung, and the spleen. Five irradiation techniques were simulated: whole breast radiotherapy 50 Gy in
25 fractions using physical wedge or breast IMRT, 3D-CRT partial breast radiotherapy 38.5 Gy in 10 fractions, HDR
brachytherapy delivering 34 Gy in 10 treatments, or Permanent Breast
103Pd Seed Implant delivering 90 Gy.
Results: For external beam radiotherapy the wedge compensation technique yielded the largest doses to internal
organs like the spleen or the heart, respectively 2,300 mSv and 2.7 Gy. Smaller scatter dose are induced using
breast IMRT, respectively 810 mSv and 1.1 Gy, or 3D-CRT partial breast irradiation, respectively 130 mSv and 0.7 Gy.
Dose to the lung is also smaller for IMRT and 3D-CRT compared to the wedge technique. For multicatheter HDR
brachytherapy a large dose is delivered to the heart, 3.6 Gy, the spleen receives 1,171 mSv and the lung receives
2,471 mSv. These values are 44% higher in case of a balloon catheter. In contrast, breast seeds implant is
associated with low dose to most internal organs.
Conclusions: The present data support the use of breast IMRT or virtual wedge technique instead of physical
wedges for whole breast radiotherapy. Regarding partial breast irradiation techniques, low energy source
brachytherapy and external beam 3D-CRT appear safer than
192Ir HDR techniques.
Background
Breast is the most common site of cancer in women and
with the wide-spread use of mammography more than
two-thirds of breast cancersa r ed i a g n o s e da ta ne a r l y
stage [1,2]. Early stage breast cancer carries a better
prognosis, with outcomes having improved dramatically
over the last two decades with a 25% reduction of breast
cancer mortality [3]. As patients diagnosed with breast
cancer are more likely to survive longer, it is essential to
prevent treatment induced fatalities. The main types of
radiation therapy induced fatalities that have been
widely reported are cardiomyopathy and secondary can-
cers [4]. Though their occurrence is also influenced by
lifestyle and/or a predisposing genetic condition [5,6], it
is primarily related to the amount of dose deposited in
specific organs [6,7]. So the most efficient way to pre-
vent these sequelae is to reduce the amount of dose
scattered to internal organs; for example, choosing a
radiation technique that minimizes the exposure of
internal organs [5-7]. In regards to secondary cancers, a
recent review from Xu et al. showed that secondary
tumors occur more frequently in organs that are close
to radiation fields, in the high/intermediate dose zones
[7], and that it is important to assess the scattered dose
to those internal organs along with their secondary can-
cer susceptibility in selecting a radiation technique. In
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published by Schultz-Hector stresses the risk of acute
dose as low as 1 ~ 2 Gy and a dose-dependent cardiac
mortality below 10 Gy [8].
On the other hand, for adjuvant breast radiotherapy,
several innovations and new paradigm have been intro-
duced over the last decade. Physical wedge were
replaced by virtual wedges, and eventually the dose dis-
tribution homogeneity was improved using breast Inten-
sity Modulated Radiation Therapy (IMRT) [9]. Multiple
techniques have been proposed for Accelerated Partial
Breast Irradiation (APBI) of early stage breast cancer
[10,11], which include high dose rate multi-catheter bra-
chytherapy and permanent breast seed implant (PBSI),
intra-operative radiotherapy using kilovoltage generator
or direct electron beam, and 3D-conformal radiotherapy
[12-17].
All of these techniques deliver different levels of scat-
ter doses to internal organs and hence may induce dif-
ferent risks of secondary cancers or cardiomyopathy.
The purpose of this paper is to evaluate the amount of
scattered dose to internal organs situated in the inter-
mediate/high dose region including the heart, the lung,
the contralateral breast and the spleen for different tech-
niques of adjuvant radiotherapy for a typical left sided
breast cancer. To avoid confounding factors linked to
patient’s anatomical characteristics and assess internal
organ dose deposition accurately, we used Monte Carlo
simulation in an anthropomorphic phantom based on a
realistic patient anatomy.
Methods
1 Radiotherapy protocols
Five different breast irradiation protocols were selected:
a standard whole breast radiotherapy delivering 50 Gy
in 25 treatments to the breast alone, using either physi-
cal wedge or virtual wedge/breast IMRT for missing tis-
sue compensation [9,18], partial breast 3D-conformal
radiotherapy (3D-CRT) delivering 38.5 Gy in 10 treat-
ments [17], multi-catheter High Dose Rate (HDR) bra-
chytherapy delivering 34 Gy in 10 treatments to the 85%
isodose [11,12], and permanent breast seed implants
with
103Pd seeds delivering a dose of 90 Gy on the Plan-
ning Target Volume (PTV) [14].
2 Realistic anthropomorphic phantom
A realistic anthropomorphic phantom of a female chest
was described in the data entry card of the MCNP
Monte Carlo code [19]. This phantom mimicked the
planning CT of a small breasted patient randomly
selected from the treatment planning database. The geo-
metry modeled was of a typical early stage cancer in the
left breast. Complex volumes were build using elemen-
tary surfaces combination to create breasts, lungs, heart,
chest walls, spleen and other body volumes. Small sphe-
rical tally volumes (0.5 to 0.8 cc) were placed in the left
and right breasts, on the anterior part of the heart cor-
responding to the left anterior descending coronary
artery [20], and in the posterior part of the ipsilateral
lung. A larger spherical tally volume (150 cc) was placed
at the position of the spleen, about 5 cm inferiorly to
the breast field edge. The MCNP *F8 pulsed height tally
function corrected for energy deposition was used to
calculate the amount of energy absorbed in each tally
volume. This function calculates for each tally the
amount of energy deposited minus the energy leaving
the volume. Previous work done by our group demon-
strated the accuracy of this method in estimating the
absorbed dose [21]. These values were converted into
dose, accounting for the energy absorbed in the treated
breast and the treatment protocol. To facilitate compari-
son with previously published data, the doses were
expressed in Gy (J kg
-1) when discussing the risk of car-
diomyopathy, and in mSv when discussing the risk of
secondary cancers.
3 External beam radiotherapy
3.1 Hybrid method
Head leakage and room scatter contributions are chal-
lenging to assess using Monte Carlo simulation because
of the very low probability for a photon to reach a
detector inside the phantom. So a hybrid method was
used to calculate the scatter dose for external beam
radiotherapy techniques. This method adds the dose
corresponding to head leakage and room back-scatter
measured in a water phantom to the scatter dose pro-
duced in beam modifiers and internal phantom scatter
calculated using Monte Carlo simulation.
3.2 Head leakage and room back-scatter
The head leakage and room back-scatter contributions
were measured in a solid water phantom (Gammax
RMI, Middleton, WI) using a Farmer ionization cham-
ber (model 2571). The phantom was placed at a source-
axis distance of 100 cm, laterally abutting the central
axis of half beam irradiation fields of various sizes: 16 ×
20 and 8 × 20 cm
2. Doses were measured at 5 cm depth
i nt h ep h a n t o ma n da t2 . 5 ,7 ,1 0 ,1 9a n d2 8c ma w a y
from the beam axis. These scatter doses were interpo-
lated for each field size using a power law.
3.3 Scatter contribution
Dose contributions due to photons scattering from
beam modifiers and/or inside the phantom were simu-
lated using the MCNP Monte Carlo code [19]. The
photon energy phase-space from a Siemens Primus
(Walnut Creek, CA) 6 MV accelerator was pre-calcu-
l a t e d[ 2 2 ] .T w oo p p o s e dp a r a l l e lb e a m sd e s c r i b e da s
being tangential to the chest wall with a 1 cm lung mar-
gin. Field sizes were 16 × 20 cm
2 for whole breast
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2 for the 3D-CRT partial
breast irradiation technique. Missing tissue compensa-
tion technique used either 30°steel wedges (r =7 . 8 1g .
cm
-3), or field in field segments for about 20% of the
dose, the remaining 80% was delivered using open
beams. This was done to simulate a virtual wedge/breast
IMRT technique.
4 Brachytherapy
4.1 Catheter
192Ir HDR brachytherapy
Ap h o t o ne n e r g ys p e c t r u mw i t hd i s c r e t ee n e r g yp r o b -
abilities corresponding to
192Ir decay was described in
the source card. Photons were emitted in 4 π starting
randomly from the source placed in the middle of the
left breast. The number of photons that were generated
was calculated based on the dwell time needed to treat
a target volume of 3 cm radius (113 cc), corresponding
to a volume of 113 cc, using a 10 Ci source. The Nucle-
tron Plato treatment planning system (Veenendaal,
Netherland) was used to calculate the total dwell time,
placing catheter evenly spaced every cm across the tar-
get volume. In this later case the IPSA dose optimiza-
tion algorithm was used to generate the dwell positions,
to deliver the prescribed dose to the target volume and
calculate the total treatment time [23].
4.1 Permanent breast seed implants (PBSI)
The same target volume geometry was used to simulate
the PBSI case. A target volume of 113 cc requires a
hundred
103Pd seeds of 2.7 U, corresponding to a total
activity of 0.2088 Ci to deliver a dose of 90 Gy on the
minimal peripheral dose [14].
5 Risk of secondary cancers estimation
The lifetime probabilities of developing fatal secondary
malignancies were calculated per Sv absorbed in breast
and lung using the National Council on Radiation
Protection and Measurements (NCRP) report 116
Table Seven Part Two page 32 [24].
6 Estimation of statistical errors
A typical Monte Carlo result represents the average of
the contributions from many particles histories. To cal-
culate this average and the standard deviation the initial
problem is divided in several smaller batches. A stan-
dard error, R, is then calculated as being the ratio
between the standard deviation and the average:
R
S
x
x = . A standard error below 5% is generally consid-
ered reliable for most calculation. For the current
study, the transport of 10
9 photons sources was simu-
lated for each opposed beam in order to get reliable
estimation of the scattered dose, i.e. with standard
error below 1%.
Results
Figures 1-a and 1-b show the small breasted patient CT
scan and its corresponding phantom designed with
MCNP. Overall the phantom was 12 cm height, 26 cm
wide and 70 cm long. The breast volumes were 520 cc,
corresponding to a typical small/medium breasted
patient in a cohort of women treated in a controlled
randomized trial in two Canadian institutions [9].
Figure 2 shows the head leakage contribution mea-
sured outside the beam boundaries at 5 cm depth in a
solid water phantom for the two different field sizes.
This contribution is very small, dropping rapidly below
1 %o ft h et o t a ld o s ea st h ed i s t a n c ef r o mt h ef i e l de d g e
increase. There is a 20% dose increase for the largest
field size that is probably due to the room back-scatter.
Table 1 summarizes the relative contribution to inter-
nal organ doses from internal photon scatter, beam
modifiers and head leakage for two external beam XRT
techniques. The internal scatter is the dominating con-
tribution to the total body dose for breast IMRT while
the photon scatter in the wedge compensator accounts
for the majority of the scattered dose using physical
wedge beam modifiers. Overall, the presence of a physi-
cal wedge dramatically increased the dose to most
organs outside the treated volume by 50 to 800% com-
pared to breast IMRT.
Table 2 compares the dose to selected organs for the
various adjuvant breast radiotherapy protocols. There
are very large variations of the total body dose between
techniques.
- For external beam radiotherapy the physical wedge
compensation technique yields the largest dose to neigh-
boring solid organs like the spleen or the heart giving
respectively 2,356 mSv and 3.0 Gy respectively. Breast
IMRT reduces the dose these neighboring organs to 866
mSv and 1.4 Gy respectively, and partial breast irradia-
tion using 3D-CRT is the safest technique with doses of
130 mSv and 0.7 Gy respectively. The dose scattered in
the lung is small for IMRT and 3D-CRT, but higher for
the wedge technique.
- For partial left breast irradiation using
192Ir HDR
brachytherapy large doses are scattered to the heart (3.6
Gy), the spleen (1,171 mSv), and the lung (2,471 mSv).
Using a balloon catheter these doses are increased by
44% reaching 5.2 Gy to the heart, 1,686 mSv to the
spleen and 3,558 mSv to the posterior part of the ipsilat-
eral lung. In contrast, permanent breast seeds implant
brachytherapy using low energy source is associated
with low doses to most organs despite a higher physical
dose is delivered to the target volume. The brachyther-
apy techniques tend to deliver higher dose to the lung
compared to external beam techniques where shielding
is used.
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This report shows that depending on the radiotherapy
techniques large variations, e.g. up to 20 fold for the
ipsilateral lung and 800 fold for the contralateral breast,
are found in the amount of scattered dose to the organs
depending on the adjuvant breast radiation technique.
The objective of this work was not to describe the range
of scatter doses received by adjuvant breast radiother-
apy, since this amount is also highly dependant on other
factors including the breast size and side, the location of
the surgical cavity for brachytherapy techniques, and the
patient body shape and size [5,18]. For example we pre-
viously reported up to a 10 fold variation in the dose
scattered in the contralateral breast in a prospective
study measuring the scatter dose to various body loca-
tions in patients receiving standard external beam radio-
therapy [18]. To evaluate the long term risks of breast
radiotherapy, we compared the scattered dose produced
by various radiotherapy techniques while keeping the
patient geometry constant. We purposely selected a
small left breasted patient to compare the amount of
scattered dose for partial breast radiotherapy techniques
versus standard whole breast radiotherapy in a worse
case scenario.
In regards to secondary cancer, to appreciate the clini-
cal significance of scattered dose one can refer to the
critical review published by Eric Hall in 2005 about the
increased risk of secondary cancers using conformal
IMRT instead of 3D-CRT [5]. In this report, lifetime
probabilities of developing fatal secondary malignancies
were calculated per Sv absorbed in various organ sites
using the National Council on Radiation Protection and
Measurements (NCRP) report 116 [24]. Using the same
methodology for our study patient, the Table 3 shows
the lifetime risk of secondary contralateral breast or
lung cancers.
For the clinical case used in this study the incremental
risk of secondary cancer breast cancer is calculated
0.34% for a whole breast technique and wedge compen-
sators. This is likely undetectable compared to the
observed frequency of contralateral breast cancer which
is about 7% at 10 years and 10% at 15 years [25,26]. For
example Obedian did not find significant difference in
Figure 1 Planning CT-scan of a typical early stage breast cancer patient with left breast involvement (1-a) and the corresponding
volumes described for the Monte Carlo simulation (1-b). The pink circles correspond to the Tally detectors placed in the breasts, ipsilateral
lung, anterior part of the heart, and the spleen.
Figure 2 Relative head leakage and room back scatter
contributions measured in a solid water phantom.
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in a retrospective series of 2,416 patients treated with
breast conserving surgery and adjuvant radiotherapy or
mastectomy without radiotherapy [26]. Though this risk
might be higher for younger women or patients with
predisposing genetic risks [6,25,27], it remains difficult
to detect. Moreover, compared to physical wedge com-
pensation radiotherapy the other techniques, especially
the ones delivering partial breast irradiation, yield at
least 7 times less scatter dose. So the risk of developing
a contralateral breast cancer should be truly
undetectable.
For a whole breast technique using physical wedge
compensation the lifetime incremental risk of lung can-
cer is calculated at 0.49%. This value is little higher but
o ft h es a m eo r d e ro fm a g n i t u d et h a nt h e0 . 3 0 %
increased risk for adjuvant radiotherapy found by
Zablotska on a cohort of 260,000 patients included in
the Surveillance Epidemiology and End Results (SEER)
database [28]. This difference could be due to the high
dose gradient in the lung, the choice of a small breasted
women and the position of the detector in the ipsilateral
lung that all could increase the amount of scatter dose
detected. Nevertheless, from a clinical perspective those
rates are small and the risk remains acceptable. Since
most radiotherapy techniques except the HDR bra-
chytherapy are yielding similar or lower amount of
radiation scatter to the lung they should also be deemed
acceptable. The only scenario where a large scatter dose
is found in the lung is
192Ir HDR brachytherapy. This is
likely due to the limited absorption in the lung tissue of
the high energy photons (average energy 367 keV) that
are emitted in all directions and without shielding from
the
192Ir source. The risk of secondary lung cancer cal-
culated in this case is increased by a factor 4, with 2 in
100 women at risk of developing lung cancer.
Regarding cardiac risk, a recent critical review pub-
lished by Schultz-Hector suggest that acute single dose
of 1~2 Gy to the heart increased the risk of developing
ischemic heart disease significantly [8]. And the excess
relative risk could be linearly fitted with a slope of 17%
per Gy. Bearing in mind those values, external beam
radiotherapy with physical wedge compensation and
HDR breast brachytherapy which yield excess dose to
the heart are deemed inappropriate breast adjuvant
radiotherapy techniques. Since the use of
103Pd has a
strong protecting effect on the heart dose, the low
energy photons being absorbed rapidly in the tissue,
alternative sources like low energy electronic or
169Yb
sources should be considered for HDR applications
[29,30].
Conclusions
Since the majority of women eligible for breast conser-
ving therapy have improved outcomes, they are likely to
live long enough to develop secondary cancers or car-
diac failures and it is important to prevent those mor-
bidities when considering a new technique. Whole
breast radiotherapy, breast IMRT and virtual wedges
appears safer than physical wedge compensation, and
for partial breast irradiation techniques, external beam
3D-CRT and low energy source brachytherapy appear
safer than
192Ir HDR techniques.
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Table 1 Relative contribution from head compensator,
leakage and internal scatter to the dose to various
organs
Technique Breast wedges Breast IMRT
Internal
scatter
Compensator Head
leakage
Internal
scatter
Head
leakage
Contralateral
breast
11.7% 87.8% 0.5% 95.6% 4.4%
Spleen 34.7% 64.7% 0.5% 98.5% 1.5%
Ipsilateral
lung
18.7% 79.2% 2.1% 90.1% 9.9%
Heart
(anterior 1/3)
38.9% 60.1% 1.0% 97.6% 2.4%
Table 2 Dose to various organs for various breast
radiotherapy techniques
Technique PBSI HDR
(catheters)
Wedge IMRT 3D-
CRT
Treated Breast 90 Gy 34 Gy 50 Gy 50 Gy 38.5 Gy
Contralateral
Breast
2.2
mSv
230 mSv 1695
mSv
206
mSv
140
mSv
Spleen 44 mSv 1171 mSv 2300
mSv
810
mSv
130
mSv
Ipsilateral lung 790
mSv
2471 mSv 582 mSv 121
mSv
80 mSv
Heart (LAD) 0.7 Gy 3.6 Gy 2.7 Gy 1.1 Gy 0.7 Gy
Table 3 Lifetime risk of secondary cancers for various
breast radiotherapy techniques using the likelihoods
from the National Council on Radiation Protection and
Measurements (NCRP) Report 116 Table 7.2, page 32
Cancer
type
Probability
(%/Sv)
PBSI HDR
(catheters)
Wedge IMRT 3D-CRT
Breast 0.20 0.00% 0.05% 0.34% 0.04% 0.03%
Lung 0.85 0.67% 2.10% 0.49% 0.10% 0.07%
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